ImmunoVaccine Inc. | Mutual Funds
Mutual Funds that own ImmunoVaccine Inc.
Asperior Investment Funds - CF Ruffer Absolute Return Fund
3,336,458
7.77%
0
0.39%
09/29/2017
CF Ruffer Investment Funds - Total Return Fund
1,794,332
4.18%
0
0.37%
04/30/2018
Ruffer SICAV - UK Mid & Smaller Companies Fund
197,031
0.46%
0
0.31%
09/15/2017
IA Canadian Equity Growth Fund
102,962
0.24%
0
0.12%
08/31/2018
83,218
0.19%
0
0.33%
08/31/2018
Barometer Long Short Equity Pool
76,969
0.18%
76,969
1.33%
12/31/2017
66,406
0.16%
66,406
0.13%
06/30/2017
IA Canadian Equity Small Cap
61,156
0.14%
0
0.28%
08/31/2018
IA Diversified
45,950
0.11%
-6,400
0.02%
08/31/2018
Exemplar Leaders Fund
36,905
0.09%
6,811
0.7%
06/30/2018
| Address |
130 Eileen Stubbs Avenue
Dartmouth Nova Scotia B3B 2C4
Canada
|
|
Employees
|
- |
| Website |
http://www.imv-inc.com |
| Updated |
07/08/2019 |
| IMV, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm's patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada. |
